A phase 1 study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer

CONCLUSIONS: Acapatamab was safe and tolerated and had a manageable CRS profile. Preliminary signs of efficacy with limited durable antitumor activity were observed. Acapatamab demonstrated pharmacokinetic and pharmacodynamic activity.PMID:38300720 | DOI:10.1158/1078-0432.CCR-23-2978

Source: Clinical Cancer Research - February 1, 2024 Category: Cancer & Oncology Authors: Tanya Dorff Lisa G Horvath Karen Autio Alice Bernard-Tessier Matthew B Rettig Jean-Pascal Machiels Mehmet A Bilen Martijn P Lolkema Nabil Adra Sylvie Rottey Richard Greil Nobuaki Matsubara Daniel S W Tan Alvin Wong Hiroji Uemura Charlotte Lemech Johannes Source Type: research